Show simple item record Glass, Oliver Kent Bowie, Michelle Fuller, Julie Darr, D Usary, J Boss, K Choudhury, KR Liu, X Zhang, Z Locasale, JW Williams, C Dewhirst, MW Jones, LW Seewaldt, V 2017-12-07T16:42:15Z 2017-12-07T16:42:15Z 2017-01-01
dc.identifier.citation Oncotarget, 2017, 8 (60), pp. 100989 - 101004
dc.description.abstract © Glass et al. Exposure to exercise following a breast cancer diagnosis is associated with reductions in the risk of recurrence. However, it is not known whether breast cancers within the same molecular-intrinsic subtype respond differently to exercise. Syngeneic mouse models of claudin-low breast cancer (i.e., EO771, 4TO7, and C3(1)SV40Tagp16- luc) were allocated to a uniform endurance exercise treatment dose (forced treadmill exercise) or sham-exercise (stationary treadmill). Compared to shamcontrols, endurance exercise treatment differentially affected tumor growth rate: 1- slowed (EO771), 2- accelerated (C3(1)SV40Tag-p16-luc), or 3- was not affected (4TO7). Differential sensitivity of the three tumor lines to exercise was paralleled by effects on intratumoral Ki-67, Hif1-a, and metabolic programming. Inhibition of Hif1-α synthesis by the cardiac glycoside, digoxin, completely abrogated exerciseaccelerated tumor growth in C3(1)SV40Tag-p16-luc. These results suggest that intratumoral Hif1-α expression is an important determinant of claudin-low breast cancer adaptation to exercise treatment.
dc.format.extent 100989 - 101004
dc.relation.ispartof Oncotarget
dc.relation.isversionof 10.18632/oncotarget.21054
dc.title Differential response to exercise in claudin-low breast cancer
dc.type Journal Article
pubs.issue 60
pubs.organisational-group /Duke
pubs.organisational-group /Duke/Pratt School of Engineering
pubs.organisational-group /Duke/Pratt School of Engineering/Biomedical Engineering
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Basic Science Departments
pubs.organisational-group /Duke/School of Medicine/Basic Science Departments/Pharmacology & Cancer Biology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine/Medicine, General Internal Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Pathology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Radiation Oncology
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Cancer Institute
pubs.organisational-group /Duke/Temp group - logins allowed
pubs.publication-status Published
pubs.volume 8
dc.identifier.eissn 1949-2553

Files in this item

This item appears in the following Collection(s)

Show simple item record